Press "Enter" to skip to content

Docs’ Risk From Patients’ Obesity; ViV on Stentless Aortic Valves; Sapien 3 Ultra OK’d

Operators’ radiation exposure was 7-fold higher during coronary angiography on patients with BMI values over 40 versus those of normal weight. (Circulation: Cardiovascular Intervention)

One center reported good outcomes with valve-in-valve TAVR after a stentless bioprosthetic valve fails. Aortic insufficiency was the primary mode of device failure for such patients. Short- and long-term mortality matched peers who got stented valves. (Catheterization and Cardiovascular Interventions)

The Sapien 3 Ultra valve won FDA approval last week for transcatheter aortic valve replacement (TAVR) in patients at intermediate or greater surgical risk. Read MedPage Today‘s story here.

TAVR for severe, symptomatic aortic stenosis carries a higher adverse event risk with concomitant mitral stenosis. The difference emerged within 30 days and lasted out to 1 year after the procedure, a study reported in the European Heart Journal.

Patients getting treated for an acute ischemic stroke had higher mortality rates and were less likely to receive thrombolytics if they had a known cancer diagnosis. Mechanical thrombectomy utilization generally didn’t appear to be affected, except in the case of brain cancer. (Journal of NeuroInterventional Surgery)

A susceptibility vessel sign present on T2*-gradient echo imaging sequence for MRI predicted recanalization success and early clinical improvement after mechanical stroke thrombectomy, according to a study in Stroke.

The MitraClip and other transcatheter tricuspid valve intervention devices were associated with 3.6% mortality at 30 days for high-risk patients with severe tricuspid regurgitation in a registry. The greater the coaptation depth, the lower the odds of device success, researchers found. (JACC: Cardiovascular Interventions)